Gate Bioscience: Funding, Investors & Team (Oct 2026)

Gate Bioscience is a biotech company that is developing a new type of medicine called Molecular Gates. These drugs are small molecules that selectively remove harmful extracellular proteins from inside the cell, where they originate. There are more than 4,000 extracellular proteins produced by humans, and over 1,000 of them can cause diseases when they function incorrectly. Molecular Gates aim to eliminate these disease-causing proteins, thereby eradicating the associated diseases for patients. The mechanism of action for Molecular Gates is unique, as they bind to a single channel in the cell through which extracellular proteins pass when they are secreted. By creating a "gate" in this channel, the Molecular Gates can block and recognize specific disease-causing proteins, preventing their exit from the cell. Consequently, the harmful proteins are degraded by the cell rather than being secreted. Gate Bioscience's mission to develop Molecular Gate medicines is supported by Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. For more information, visit www.gatebio.com.

Gate Bioscience has raised $125M across 2 rounds on record. The most recent is a Series B of $65.0M announced in Nov 2025.

Gate Bioscience's most recent funding round on record is a Series B of $65.0M, announced in Nov 2025.

Jordi Mata Fink is listed as CEO at Gate Bioscience.

Gate Bioscience is based in Brisbane, California, United States.

Gate Bioscience is in the 11-50 employee band.

Gate Bioscience's latest round of $65.0M is above the $8.6M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.